Chem. J. Chinese Universities ›› 2013, Vol. 34 ›› Issue (12): 2752.doi: 10.7503/cjcu20130284

• Organic Chemistry • Previous Articles     Next Articles

Synthesis, Characterization and Antidiabetic Activities of Novel Genipin Derivatives

LI Zhi-Wei1,2, BAO Zhi-Chao1, WANG Jian-Nan1, CAO Rui-Feng1, XIE Zhao-Yang1, ZHENG Qun-Yi1,3   

  1. 1. Natsource Chemicals(Changsha) Corporation, Changsha 410329, China;
    2. School of Chemistry and Biological Engineering, Changsha University of Science & Technology, Changsha 410114, China;
    3. School of Pharmaceutical Science, Hunan Academy of Chinese Medicine, Changsha 410208, China
  • Received:2013-03-26 Online:2013-12-10 Published:2013-10-11

Abstract:

Diabetes has become the third major diseases threat to human's health and safety after cancer, cardiovascular and cerebrovascular diseases. The currently used drugs are difficult to completely cure the disease, and the long-term use is easy to produce side effects and drug resistance. So, it is very important to research and development a new kind of drug to treat the diabetes. The extract of gardenia and fruit containing the active ingredient genipin showed a very good effect in the traditional Chinese medicine treating the diabetes. In order to find novel anti-diabebes molecules, two core compounds containing amine group were synthesized from the commercial available genipin by methylation(benzylation), substitution with methylsulfonyl chloride followed by sodium azide and reduction. Thirteen novel compounds were obtained by reacting the two core compounds with a variety of acyl chlorides. The total yields were between 41% and 63%. Their structures were characterized by NMR, ESI-MS and elemental analysis and anti-dibiatic activities were evaluated by DPP Ⅳ assay at a concentration of 10 mmol/L. The results showed that all the title compounds exhibited certain extent inhibitory activities against DPP Ⅳ. Among them, compound 10f showed higher inhibitory rate up to 31.2%.

Key words: Diabetes, Genipin, Inhibitor

CLC Number: 

TrendMD: